Compositions and methods of enhancing anti-tumor response using hybrid neutrophils

A method of inhibiting tumor growth in a subject, the method comprising

• (a) administering to the subject an effective amount of an anti-tumor antibody or an antigen-binding fragment thereof;
• and
• (b) administering to the subject an effective amount of a hybrid neutrophil, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of:
• arginase-1 (Arg1), myeloperoxidase (MPO), CD66b, and CD15, and at least one antigen presenting cell (APC) associated molecule selected from the group consisting of:
• CD14, HLA-DR, CD32, CD64, and CD89, thereby inhibiting tumor growth in the subject.

A method of increasing efficacy of an antibody against a tumor in a subject, the method comprising

• (a) administering to the subject an effective amount of an anti-tumor antibody or an antigen-binding fragment thereof;
• and
• (b) administering to the subject an effective amount of a hybrid neutrophil, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of:
• Arg1, MPO, CD66b, and CD15, and at least one antigen presenting cell (APC) associated molecule selected from the consisting of:
• CD14, HLA-DR, CD32, CD64, and CD89, thereby increasing efficacy of the antibody against the tumor in the subject.

A method of treating a tumor in a subject, the method comprising

• (a) administering to the subject an effective amount of an anti-tumor antibody or an antigen-binding fragment thereof;
• and
• (b) administering to the subject an effective amount of a hybrid neutrophil, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of:
• Arg1, MPO, CD66b, and CD15, and at least one antigen presenting cell (APC) associated molecule selected from the group consisting of:
• CD14, HLADR, CD32, CD64, and CD89, thereby treating the tumor in the subject.